Stohl W, Hofman F M, Gray J D
Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033.
J Immunol. 1990 Aug 15;145(4):1078-87.
We used three anti-human anti-CD3 mAb each recognizing different surface CD3 epitopes to differentially perturb the CD3/TCR complex on the surface of Jurkat T cells. In the presence of phorbol ester, these anti-CD3 mAb triggered differential IL-2 production in Jurkat T cells, which could not be explained by differences in kinetics of IL-2 production, by differences in IL-2 adsorption caused by differential surface expression of p55 or p75 IL-2R, by effects on IL-2 secretion rather than actual synthesis, or by differential toxicities of the anti-CD3 mAb to Jurkat cells. In addition, this differential anti-CD3-induced IL-2 production could not be explained by differences in mAb isotype or in avidities of the anti-CD3 mAb for the Jurkat cells. Moreover, anti-CD3 mAb covalently immobilized onto beads also differentially induced IL-2 production in Jurkat cells, suggesting that the differential IL-2 response is not based on differential rates of anti-CD3-induced modulation of Jurkat cell surface CD3. Although differences among the anti-CD3 mAb in the initial rates of binding to Jurkat cell were observed, this was also believed unlikely to explain the differential IL-2 response. Regardless of the anti-CD3 mAb used, anti-CD3-induced total inositol phosphate (IP) production did not necessarily correlate with anti-CD3-induced IL-2 production. Nevertheless, despite the differences among the anti-CD3 mAb in inducing IL-2 production, the calcium responses were grossly similar. Taken together, these observations indicate that CD3/TCR-mediated IL-2 production in Jurkat cells can be dissociated from total IP generation, and the basis of differential CD3/TCR-mediated IL-2 production in these cells does not appear to be at the level of the initial activation-induced calcium response. These studies suggest that the nature of the CD3/TCR ligand (its physical form and/or the specific epitope it perturbs) can either directly influence intracellular events distal to the generation of IP and increase in intracellular free calcium leading to differential IL-2 production or can trigger IP-independent pathways that affect IL-2 production.
我们使用了三种抗人抗CD3单克隆抗体,每种抗体识别不同的表面CD3表位,以差异性地干扰Jurkat T细胞表面的CD3/TCR复合物。在佛波酯存在的情况下,这些抗CD3单克隆抗体在Jurkat T细胞中引发了差异性的白细胞介素-2(IL-2)产生,这无法通过IL-2产生动力学的差异、由p55或p75 IL-2受体的差异性表面表达引起的IL-2吸附差异、对IL-2分泌而非实际合成的影响,或抗CD3单克隆抗体对Jurkat细胞的差异性毒性来解释。此外,这种差异性的抗CD3诱导的IL-2产生无法通过单克隆抗体的同种型差异或抗CD3单克隆抗体对Jurkat细胞的亲和力差异来解释。此外,共价固定在珠子上的抗CD3单克隆抗体也在Jurkat细胞中差异性地诱导IL-2产生,这表明差异性的IL-2反应并非基于抗CD3诱导的Jurkat细胞表面CD3调节速率的差异。尽管观察到抗CD3单克隆抗体与Jurkat细胞结合的初始速率存在差异,但这也被认为不太可能解释差异性的IL-2反应。无论使用哪种抗CD3单克隆抗体,抗CD3诱导的总肌醇磷酸(IP)产生不一定与抗CD3诱导的IL-2产生相关。然而,尽管抗CD3单克隆抗体在诱导IL-2产生方面存在差异,但钙反应总体上相似。综上所述,这些观察结果表明,Jurkat细胞中CD3/TCR介导的IL-2产生可以与总IP生成解离,并且这些细胞中差异性的CD3/TCR介导的IL-2产生的基础似乎不在初始激活诱导的钙反应水平。这些研究表明,CD3/TCR配体的性质(其物理形式和/或它干扰的特定表位)可以直接影响IP产生和细胞内游离钙增加之后的细胞内事件,导致差异性的IL-2产生,或者可以触发影响IL-2产生的IP非依赖性途径。